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Abstract: Gestational diabetes mellitus (GDM) is a common disease
in pregnancy causing maternal and fetal complications. To prevent
these adverse outcomes, optimal screening and diagnostic criteria
must be adequate, timely, and efficient. This study suggests a novel
approach that is practical, efficient, and patient- and clinician-friendly
in predicting adverse outcomes of GDM. The authors conducted a
retrospective cohort study via medical record review of patients
admitted between March 2001 and April 2013 at the Severance
Hospital, Seoul, South Korea. Patients diagnosed by a conventional
2-step method were evaluated according to the presence of adverse
outcomes (neonatal hypoglycemia, hyperbilirubinemia, and hyperin-
sulinemia; admission to the neonatal intensive care unit; large for
gestational age; gestational insulin therapy; and gestational hyperten-
sion). Of 802 women who had an abnormal 50-g, 1-hour glucose
challenge test, 306 were diagnosed with GDM and 496 did not have
GDM (false-positive group). In the GDM group, 218 women (71.2%)
had adverse outcomes. In contrast, 240 women (48.4%) in the false-
positive group had adverse outcomes. Women with adverse outcomes
had a significantly higher body mass index (BMI) at entry (P¼ 0.03)
and fasting blood glucose (FBG) (P¼ 0.03). Our logistic regression
model derived from 2 variables, BMI at entry and FBG, predicted
GDM adverse outcome with an area under the curve of 0.642,
accuracy of 61.3%, sensitivity of 57.2%, and specificity of 66.9%
compared with the conventional 2-step method with an area under the
curve of 0.610, accuracy of 59.1%, sensitivity of 47.6%, and speci-
ficity of 74.4%. Our model performed better in predicting GDM
adverse outcomes than the conventional 2-step method using onlyhD, Ja-Young Kwo
m, MD, PhD, and Hee Young Cho, MD
(Medicine 95(1):e2204)
Abbreviations: ACOG = American Congress of Obstetricians and
Gynecologists, AUC = area under the curve, BMI = body mass
index, FBG = fasting blood glucose, GCT = glucose challenge test,
GDM = gestational diabetes mellitus, GTT = oral glucose tolerance
test, HAPO = Hyperglycemia and Adverse Pregnancy Outcomes.
INTRODUCTION
G estational diabetes mellitus (GDM), defined as glucoseintolerance with onset during pregnancy, is a common
disease affecting approximately 6% to 7% of pregnant
women.1,2 Pregnancies complicated by GDM have maternal
and fetal implications, including increased preeclampsia, rate of
operative delivery, and subsequent diabetes mellitus as
maternal complications.3,4 Fetal risks include macrosomia,
shoulder dystocia, other birth traumas, neonatal hypoglycemia,
and long-term sequelae such as obesity and impaired intellec-
tual achievement.5–7 To prevent these adverse outcomes,
optimal screening and diagnostic criteria must be adequate,
timely, and efficient.
Most clinicians have used the 2-step method that was
introduced in 1964 by O’Sullivan and Mahan8 for GDM screen-
ing and diagnosis. The 2-step method remains the recommen-
dation of the American Congress of Obstetricians and
Gynecologists (ACOG).1 A 1-step method, introduced by the
Hyperglycemia and Adverse Pregnancy Outcomes Study in
2008,9 however, has become an alternative option for GDM
screening and diagnosis. The 1-step method allows earlier GDM
diagnosis and treatment, thereby decreasing the risks associated
with the disease.10 Despite an association with adverse out-
comes, optimal screening and diagnostic criteria for GDM,
including both the 1- and 2-step methods, remain controver-
sial.11,12 Furthermore, both approaches, although validated by
extensive research and endorsed by experts, are extremely
demanding. The oral glucose tolerance test (GTT), whether it
is 75 or 100 g, is a costly and cumbersome test, both for patients
and clinicians. We identified several risk factors associated with
adverse outcomes, and using those risk factors, we developed a
screening tool for predicting adverse outcomes of GDM.
Because the GDM diagnostic tests are imperfect, our model
suggests an alternative approach, which is more practical,
efficient, and patient- and clinician-friendly.
MATERIALS AND METHODS
This is a retrospective cohort study conducted via medicalnts admitted between March 2001 and
rance Hospital, Seoul, South Korea. The
oard of the Yonsei University Health
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and corresponds to the strengths of the 1-step method. The
reasoning behind the shift from the 2 step to the 1 step is the
ability of the 1-step method to allow earlier GDM diagnosis and
TABLE 1. Number of Patients With or Without Adverse
Medicine  Volume 95, Number 1, January 2016System approved the protocol of this study (project no: 4–
2014–1031). No consent was given because the data were
anonymized before analysis. Eligible patients were diagnosed
with GDM via the 2-step method during a current pregnancy.
Exclusion criteria were preexisting type 1 or type 2 diabetes and
diagnosis with GDM at <24 weeks’ gestation. Multiple
gestations, anomalous fetuses, and patients with chronic hyper-
tension were also excluded. In our institution, we have used the
2-step method following the ACOG recommendation. Gesta-
tional diabetes mellitus was defined as 2 or more of the 4 values
(fasting, 1 hour, 2 hours, or 3 hours) being abnormal on the 100-
g, 3-hour GTT in a patient with an abnormal 50-g, 1-hour
glucose challenge test (GCT), for which fasting is not required.
Abnormal values for the 100-g, 3-hour GTT were defined as
fasting blood glucose (FBG) 95, 1-hour blood glucose 180,
2-hour blood glucose 155, and 3-hour blood glucose
140mg/dL. An abnormal value for the 50-g, 1-hour GCT
was blood glucose 140mg/dL.
Adverse outcomes included neonatal hypoglycemia,
hyperbilirubinemia, and hyperinsulinemia; admission to the
neonatal intensive care unit; large for gestational age, gesta-
tional insulin therapy; and preeclampsia or gestational hyper-
tension. Women having atleast 1 of those adverse outcomes
were considered as having adverse outcomes. Hypoglycemia
was defined as blood glucose<40mg/dL by using the heel stick
within 2 hours of birth and before the first nonbreast-feeding,
and hyperbilirubinemia was defined as a bilirubin level >5mg/
dL. Hyperinsulinemia was defined as an insulin level
>10.7mU/mL. Large for gestational age was defined as birth
weight above the 90th percentile compared with gestational age
based on sex-specific and race-specific norms. Preeclampsia
was diagnosed according to the criteria of the ACOG Practice
Bulletin: new onset of blood pressure 140/90mm Hg on 2
separate readings taken 6 hours apart after 20 gestational weeks
and proteinuria 300mg/24 hours. Gestational hypertension
was defined by criteria 1 of preeclampsia but without protei-
nuria.
Data are reported as the mean (SD) for continuous vari-
ables. For univariate analysis, the t test was used to compare
continuous variables. For multivariate analysis, we used multi-
variate models of logistic regression that included all risk
factors that were significantly associated in the univariate
analysis. We developed a model using multiple logistic
regression including body mass index (BMI), calculated as
weight (kg)/height squared (m2), and FBG. We evaluated
diagnostic abilities including not only accuracy, sensitivity,
and specificity but also area under the curve (AUC). To compare
the performance of our model with the 2-step method, we
selected as a cutoff value, the point on the receiver operating
characteristic curve closest to the upper left corner. This method
maximized the Youden index, giving equal weight to sensitivity
and specificity.13 SPSS software version 20.0 (SPSS Inc.,
Park et alChicago, IL) was used for statistical analyses, all reported Outcomes
False-Positive
Group
GDM
group Tota
Without adverse
outcomes
256 (51.6%) 88 (28.8%) 344
With adverse
outcomes
240 (48.4%) 218 (71.2%) 458P values were 2-tailed, and a P value <0.05 was considered
statistically significant.
RESULTS
Between March 2001 and April 2013, among 3434 women
who came to the hospital, 802 women had an abnormal 50-g, 1-
hour GCT, of whom 306 were diagnosed with GDM and 496
were found to not have GDM (the false-positive group; Fig. 1).
In the GDM group, 218 women (71.2%) had an adverse out-
come. In contrast, 240 women (48.4%) in the false-positive
2 | www.md-journal.comgroup had an adverse outcome (Table 1). In the false-positive
group, women with adverse outcomes had significantly higher
BMI at entry and FBG in both univariate and multivariate
analyses (Table 2). In the GDM group, women with adverse
outcomes had significantly higher glucose levels after GCT and
GTT only in the univariate analysis (Table 3).
Table 4 describes our logistic regression model derived
from 2 variables, BMI at entry and FBG, which were signifi-
cantly different in women in the false-positive group with
adverse outcomes. Our model was well calibrated (Hosmer–
Lemeshow goodness-of-fit test, P¼ 0.27). The conventional 2-
step method predicted GDM adverse outcomes with an AUC of
0.610, accuracy of 59.1%, sensitivity of 47.6%, and specificity
of 74.4%. In contrast, our model predicted GDM adverse out-
comes with an AUC of 0.642, accuracy of 61.3%, sensitivity of
57.2%, and specificity of 66.9% (Table 5). Figure 2 shows the
receiver operating characteristic curves of the conventional 2-
step method and our logistic regression model for predicting
GDM adverse outcomes.
DISCUSSION
Our logistic regression model performed better in predict-
ing GDM adverse outcomes than the conventional 2-step
method using only BMI at entry and FBG. Our model is
cost-effective, patient-friendly, and convenient because these
2 variables are simple to measure and require only 1 venipunc-
ture. The GTT in the conventional 2-step method requires
4 venipunctures and a wait period of 3 hours. With our model,
women do not have to wait for 3 hours at the hospital. Moreover,
our model compensates for the drawbacks of the 2-step method
FIGURE 1. Flow chart for diagnosing gestational diabetes in this
study population. GCT¼glucose challenge test, GDM¼gesta-
gestational diabetes, GTT¼glucose tolerance test.Total 496 306 802
GDM¼ gestational diabetes mellitus.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reservedl.
TABLE 2. False-Positive Group With or Without Adverse Outcomes
False-Positive Group
Without Adverse
Outcomes (n¼ 256)
With Adverse
Outcomes (n¼ 240) P Py
Age (y) 32.9 (3.8) 33.1(3.8) 0.66
Height (cm) 161.0 (4.9) 161.6 (4.9) 0.14
BMI at entry (kg/m2) 21.3 (3.1) 22.1 (3.9) 0.01 0.03
Parity 0.6 (0.7) 0.6 (0.7) 0.23
Glucose level after 50-g GCT (mg/dL) 151.5 (11.6) 150.5 (10.0) 0.28
FBG (mg/dL) 78.7 (8.0) 81.0 (11.6) 0.01 0.03
Glucose level after 1 hour of 100-g, 3-hour GTT (mg/dL) 143.0 (25.8) 146.7 (27.5) 0.13
Glucose level after 2 hours of 100-g, 3-hour GTT (mg/dL) 125.3 (20.8) 127.2 (23.5) 0.33
Glucose level after 3 hours of 100-g 3-hour GTT (mg/dL) 104.7 (20.9) 103.8 (23.0) 0.65
Data are shown as mean (SD) for continuous variables.
BMI¼ body mass index, FBG¼ fasting blood glucose, GCT¼ glucose challenge test, GDM¼ gestational diabetes mellitus, GTT¼ glucose
tolerance test.
s.
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disease, and its ease of administration, convenience for patients
and clinicians, and its diagnostic accuracy.10 Use of the 1-step
method began after release of the Hyperglycemia and Adverse
Pregnancy Outcomes Study findings in 2008,9 and is recom-
mended in the 2010 recommendations of the International
Association of Diabetes and Pregnancy Study Group14 and
by the American Diabetes Association in 2011.15 Our model
is more convenient than the 1-step method because it avoids the
1- and 2-hour postload measures and there is no need to wait at
the hospital. Moreover, because there is no GCT step, GDM
diagnosis and treatment can be as fast as the 1-step method.
Higher BMI at entry and FBG were selected as important
P value calculated using the t test.
yP value calculated using logistic regression for multivariate analysirisk factors for adverse outcomes. There have been various
studies indicating a significant association between higher BMI
and GDM.16–19 Torloni et al20 performed a systematic review of
TABLE 3. Gestational Diabetes Mellitus Group With or Without A
Wit
Outc
Age (y)
Height (cm)
BMI at entry (kg/m2)
Parity
Glucose level after 50-g GCT (mg/dL) 1
FBG (mg/dL)
Glucose level after 1 hour of 100-g 3-hour GTT (mg/dL) 1
Glucose level after 2 hours of 100-g 3-hour GTT (mg/dL) 1
Glucose level after 3 hours of 100-g 3-hour GTT (mg/dL) 1
Data are shown as mean (SD) for continuous variables.
BMI¼ body mass index, FBG¼ fasting blood glucose, GCT¼ glucose
tolerance test.
P value calculated using the t test.
yP value calculated using logistic regression for multivariate analysis.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.the literature and a meta-analysis and found out that the
maternal prepregnancy BMI is directly associated with the risk
of developing GDM. Insulin resistance seems to play a central
role among changes in maternal metabolism caused by obesity.
There is a report that pregnancy further exacerbated defects of
insulin receptors and postreceptors associated with obesity.21 In
addition to insulin resistance, inflammation also might be
related to the mechanism of obesity in relation to GDM.
Although the pathogenesis of GDM is not clearly understood,
several studies found higher levels of serum C-reactive protein,
interleukin-6, and ferritin in GDM, suggesting that GDM is
associated with systemic inflammation.22–24 Obesity is usually
accompanied by inflammation because of the secretion of
proinflammatory cytokines by adipocytes.25 Thus, women with
higher BMI have abundant adipocytes that produce excessive
proinflammatory cytokines and might lead to the development
dverse Outcomes
GDM Group
hout Adverse
omes (n¼ 88)
With Adverse
Outcomes (n¼ 218) P Py
33.5 (3.5) 33.7 (4.0) 0.65
159.9 (5.4) 160.6 (5.5) 0.32
22.6 (4.2) 23.7 (4.5) 0.06
0.5 (0.7) 0.7 (0.8) 0.12
65.9 (18.9) 176.8 (33.9) <0.001 0.15
91.6 (25.0) 100.9 (28.0) 0.01 0.35
91.1 (25.8) 199.5 (29.6) 0.02 0.67
72.1 (25.1) 182.3 (34.7) 0.01 0.96
34.4 (28.6) 146.5 (33.2) 0.01 0.06
challenge test, GDM¼ gestational diabetes mellitus, GTT¼ glucose
www.md-journal.com | 3
ance of that method with our model. Second, our model might
TABLE 4. Odds Ratios for Predicting Gestational Diabetes Mellitus Adverse Outcomes Using the Multiple Logistic Regression
Variables b-Coefficient Odds ratio (95% CI) P
BMI at entry (kg/m2) 0.055 1.057 (1.014–1.100) 0.01
FBG (mg/dL) 0.025 1.025 (1.015–1.036) <0.001
BMI¼ body mass index, CI¼ confidence interval, FBG¼ fasting blood
TABLE 5. Comparison of the Performance of the Convention-
al 2-Step Method and Logistic Regression in Predicting Gesta-
tional Diabetes Mellitus Adverse Outcomes
Conventional 2-Step
Method
Logistic
Regression
AUC 0.610 0.642
Accuracy 59.1% 61.3%
Sensitivity 47.6% 57.2%
Specificity 74.4% 66.9%
Park et al Medicine  Volume 95, Number 1, January 2016of GDM. Owing to the probable pathogenesis of obesity in
association with GDM as mentioned earlier, BMI at entry was
selected as a significant factor for predicting GDM adverse
outcomes.
Another significant factor for predicting GDM adverse
AUC¼ area under the curve.outcomeswas elevated FBG,which indicates insulin resistance
and impaired insulin secretion.26 An elevated FBG suggests an
underlying pathology of gestational diabetes and does not
FIGURE 2. Receiver operating characteristic curves of logistic
regression and conventional 2-step method for predicting gesta-
tional diabetes mellitus adverse outcomes. GDM¼gestational
diabetes mellitus, LR¼ logistic regression, ROC¼ receiver operat-
ing characteristics.
4 | www.md-journal.comchange throughout gestation, which offers another advantage
in its use.26,27 During the years, FBG has been widely used as a
screening test for GDM, because of its advantages of being less
expensive, reproducible, and universally easily adminis-
tered.28
Most studies have focused on investigating the optimal
factors and its values in predicting GDM.26–28 The main
strength of our study is its focus on investigating performance
for predicting GDM adverse outcomes and suggesting a more
efficient and effective prediction model. There, however,
are several limitations. First, because our institution does not
perform the 1-step method, we could not compare the perform-
glucose, GDM¼ gestational diabetes mellitus.have been fit to the study population; therefore, future studies in
other populations are needed to verify this model.
CONCLUSIONS
Our logistic regression model performed better than the
conventional 2-step method in predicting GDM adverse out-
comes. Furthermore, using only BMI at entry and FBG in our
model, we attained a practical, inexpensive, efficient, more
reproducible, easier, and patient- and clinician-friendly
approach. Further studies should be targeted to evaluating
our model in other very high-risk populations, including over-
weight, obese, African–American, and Hispanic women.
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